Since the first monoclonal antibody therapy was approved by the FDA in 1986, antibody engineering has dramatically evolved. Therapeutic antibodies have become the predominant class of biological drugs and are used to treat a variety of diseases including many types of cancer. With the development of novel bio-therapeutic antibody formats, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins, new purification challenges in the downstream process of these molecules arise.
With an altered or absent Fc-region, the use of bacterial surface proteins such as Protein A or L, is not always the most efficient solution for the purification of these novel modalities. Affinity chromatography resins, specifically developed to bind antibody subdomain regions, can provide an alternative solution in the purification process of a variety of antibody formats, thereby allowing commercial production of antibody therapeutics.
Attendees will learn: